Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating)'s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.81 and traded as low as $4.33. Cryo-Cell International shares last traded at $4.37, with a volume of 21,859 shares traded.

Wall Street Analysts Forecast Growth

Separately, Maxim Group initiated coverage on Cryo-Cell International in a research report on Monday, August 29th. They set a "buy" rating and a $12.00 target price on the stock.

Cryo-Cell International Price Performance

The company has a market capitalization of $37.23 million, a P/E ratio of 29.14 and a beta of 0.35. The company has a 50 day moving average of $5.19 and a 200-day moving average of $5.81.

Insider Activity

In other Cryo-Cell International news, CEO David Portnoy bought 20,000 shares of the stock in a transaction dated Tuesday, November 8th. The stock was purchased at an average cost of $4.89 per share, for a total transaction of $97,800.00. Following the completion of the acquisition, the chief executive officer now owns 204,080 shares of the company's stock, valued at $997,951.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders acquired 34,366 shares of company stock worth $167,193. Insiders own 33.80% of the company's stock.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV grew its holdings in shares of Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 124,135 shares of the company's stock after acquiring an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned about 1.47% of Cryo-Cell International worth $732,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 9.01% of the stock is owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

(Get Rating)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.

Featured Stories

• Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
• Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
• Santa Claus Rally? Here's What Needs to Happen
• Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
• Dark Clouds Are Gathering For Cloud Stocks
• 3 Dividend Growers With Good 2023 Growth Prospects

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.